Liminatus Pharma, Inc. LIMN
Set alert
2.52 USD -0.23 -8.36%
At close · Nov 2
2.51 -0.01 -0.40%
After hours · Nov 2, 4:15 PM ET
2.52 Day range 2.97
2.52 52-week range 141.50
- YTD
- -91.74%
- 1 year
- -96.37%
- Open
- 2.97
- Prev close
- 2.75
- Mkt cap
- 3.38M
- Vol
- 23.96K
- Avg vol
- 221.94K
- EPS
- -23.50
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.52
- High
- 2.97
2Y chart
Events in this range
- Aug 21, 2026Split: 1 for 50
Signals (43)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 28, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 30, 2026 | 4 months ago |
| SMA: Bearish | Jun 3, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
| SMA: Bullish | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | May 26, 2026 | 5 months ago |
| SMA: Bearish | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 21, 2026 | 5 months ago |
| MACD: Buy Signal | May 19, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| SMA: Bearish | May 5, 2026 | 6 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 9, 2026 | 7 months ago |
Newest 20 of 43.
Financials — quick view
LIMN Revenue — quarterly 0
LIMN Net income — quarterly -1.41M
LIMN EPS — quarterly -1.50
News
- Liminatus Pharma Regains Compliance With Nasdaq’s Minimum Bid Price Rule
- Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Liminatus Pharma Engages Synex Consulting To Support Clinical Development Of IBC101, CD19xCD22 Bivalent CAR-T Cell Therapy Candidate
- Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Liminatus Pharma Board Adopts Resolutions Approving Reverse Stock Split Of Its Common Stock At Ratio Of 1-For-50
- Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
Your note
Sign in to keep a note on LIMN — it syncs with the Stock Master app.